175 related articles for article (PubMed ID: 8556173)
1. The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation.
Bruhn HD; Zurborn KH
J Heart Valve Dis; 1995 Mar; 4(2):138-40. PubMed ID: 8556173
[TBL] [Abstract][Full Text] [Related]
2. [Measurement of prothrombin fragment F1+2 for monitoring the anticoagulant effect of phenprocoumon].
Bruhn HD; Zurborn KH
Dtsch Med Wochenschr; 1993 Jul; 118(26):967-70. PubMed ID: 8519230
[TBL] [Abstract][Full Text] [Related]
3. [Prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complex(TAT) and thrombophilia parameters in orally anticoagulated patients with inferior vena cava filters].
Halbmayer WM; Haushofer A; Toth E
Wien Med Wochenschr; 1993; 143(5):95-8. PubMed ID: 8511904
[TBL] [Abstract][Full Text] [Related]
4. Association between prothrombin activation fragment (F1.2), cerebral ischemia (S-100beta) and international normalized ratio (INR) in patients with ventricular assisted devices.
Joshi A; Magder LS; Kon Z; Kallam S; Kwon M; Sangrampurkar R; Pierson R; Poston R
Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):323-7. PubMed ID: 17669856
[TBL] [Abstract][Full Text] [Related]
5. [Value of molecular markers for administration of anticoagulant therapy after heart valve replacement].
Dahm M; Lotz J; Hafner G; Oelert H; Prellwitz W
Z Kardiol; 1998; 87 Suppl 4():42-5. PubMed ID: 9857466
[TBL] [Abstract][Full Text] [Related]
6. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
[TBL] [Abstract][Full Text] [Related]
7. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism.
Kyrle PA; Stümpflen A; Hirschl M; Bialonczyk C; Herkner K; Speiser W; Weltermann A; Kaider A; Pabinger I; Lechner K; Eichinger S
Thromb Haemost; 1997 Nov; 78(5):1327-31. PubMed ID: 9408013
[TBL] [Abstract][Full Text] [Related]
8. Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment.
Tripodi A; Cattaneo M; Molteni A; Cesana BM; Mannucci PM
Thromb Haemost; 1998 Mar; 79(3):571-3. PubMed ID: 9531043
[TBL] [Abstract][Full Text] [Related]
9. Course of thrombin activation markers in patients implanted with Palmaz-Schatz stents: first experiences with a post-interventional anticoagulation regimen.
Haushofer A; Halbmayer WM; Dittel M; Prachar H; Mlczoch J; Fischer M
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):697-706. PubMed ID: 7865675
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of Quick/INR values of whole capillary blood (CoaguChek Plus) and venous citrate plasma in patients with and without oral anticoagulation].
Burri S; Demarmels Biasiutti F; Lämmle B; Wuillemin WA
Schweiz Med Wochenschr; 1998 Oct; 128(44):1723-9. PubMed ID: 9846345
[TBL] [Abstract][Full Text] [Related]
11. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism.
Kyrle PA; Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Melichart M; Traxler G; Weltermann A; Speiser W; Lechner K
Thromb Haemost; 1997 May; 77(5):829-33. PubMed ID: 9184387
[TBL] [Abstract][Full Text] [Related]
12. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
Rombouts EK; Rosendaal FR; van der Meer FJ
Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
14. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.
Koefoed BG; Feddersen C; Gulløv AL; Petersen P
Thromb Haemost; 1997 May; 77(5):845-8. PubMed ID: 9184390
[TBL] [Abstract][Full Text] [Related]
15. [Oral contraception in protein C deficiency].
Bruhn HD
Dtsch Med Wochenschr; 1994 Aug; 119(31-32):1100. PubMed ID: 8055751
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
[TBL] [Abstract][Full Text] [Related]
17. [Is the assessment of prothrombin fragment F1+2 for monitoring of heparin therapy in patients with deep vein thrombosis useful?].
Korte W; Corbetta C; Schmid L
Schweiz Med Wochenschr; 1995 Mar; 125(9):420-3. PubMed ID: 7892570
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
[TBL] [Abstract][Full Text] [Related]
19. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination.
Bruhn HD; Conard J; Mannucci M; Monteagudo J; Pelzer H; Reverter JC; Samama M; Tripodi A; Wagner C
Thromb Haemost; 1992 Oct; 68(4):413-7. PubMed ID: 1448772
[TBL] [Abstract][Full Text] [Related]
20. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
